Praxis Precision Medicines (NASDAQ:PRAX) versus Avalo Therapeutics (NASDAQ:AVTX) Financial Contrast

Avalo Therapeutics (NASDAQ:AVTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Risk & Volatility

Avalo Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Avalo Therapeutics and Praxis Precision Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	2	10	0	2.69
Praxis Precision Medicines	2	0	17	3	2.95

Avalo Therapeutics presently has a consensus price target of $40.30, suggesting a potential upside of 440.94%. Praxis Precision Medicines has a consensus price target of $630.42, suggesting a potential upside of 143.48%. Given Avalo Therapeutics’ higher possible upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Praxis Precision Medicines.

Profitability

This table compares Avalo Therapeutics and Praxis Precision Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Valuation & Earnings

This table compares Avalo Therapeutics and Praxis Precision Medicines”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60,000.00	6,659.06	-$78.26 million	($4.37)	-1.70
Praxis Precision Medicines	$8.55 million	845.50	-$303.27 million	($12.93)	-20.02

Avalo Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.